Having trouble accessing articles? Reset your cache.

Arzerra ofatumumab: Phase II data

In a double-blind, dose-escalation, crossover Phase II trial in 26 patients initially treated with IV ofatumumab for 24 weeks and then crossed over to placebo, repeated MRI scans showed a sustained reduction

Read the full 327 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE